Clinical trial • Phase III • Other

MIDAZOLAM for Perioperative anxiety

Phase III trial of MIDAZOLAM for Perioperative anxiety.

Overview

Trial Therapeutic Area
Other
Trial Disease
Perioperative anxiety
Trial Stage
Phase III
Drug Modality
Small molecule
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
25-06-2024
First CTIS Authorization Date
10-07-2024

Trial design

Randomised, midazolam oromucosal solution (buccolam 2.5 mg oromucosal solution / midazolam rowa 2.5 mg oromucosal solution) given as premedication (oral; product info indicates dosing units mg/kg and a max total dose of 1 mg/kg), versus handheld-multimedia (tablet/ipad) distraction, versus no anxiolysis (standard care).-controlled Phase III trial in Belgium.

Randomised
Yes
Comparator
Midazolam oromucosal solution (BUCCOLAM 2.5 mg oromucosal solution / Midazolam Rowa 2.5 mg oromucosal solution) given as premedication (oral; product info indicates dosing units mg/kg and a max total dose of 1 mg/kg), versus handheld-multimedia (Tablet/iPad) distraction, versus no anxiolysis (standard care).
Target Sample Size
150

Eligibility

Recruits 150 paediatric patients.

Vulnerable Population
Children aged ≥1 and <8 years are the study population; written informed consent must be provided by the legal parents or caretaker. Assent of the child is not specified in the available documents. Population flagged in system as isVulnerablePopulationSelected: false.

Inclusion criteria

  • {"criterion_text":"- Age ≥ 1 year and <8 years old"}
  • {"criterion_text":"- ASA 1 or 2"}
  • {"criterion_text":"- Elective circumcision, tonsillectomy or adenoidectomy, dental care procedure in day-care"}
  • {"criterion_text":"- Written informed consent by the legal parents or caretaker"}

Exclusion criteria

  • {"criterion_text":"- Parents of the patient wish not to participate with the study"}
  • {"criterion_text":"- Any use of psychoactive medication"}
  • {"criterion_text":"- A known photosensitive epilepsy"}
  • {"criterion_text":"- A previous operation within 3 months of the time of scheduled operation"}
  • {"criterion_text":"- Any other contraindication for the use of the study medication"}
  • {"criterion_text":"- Previous history of multiple surgery (>3)"}
  • {"criterion_text":"- Parents are not able to give informed consent (language barrier, legally incapable)"}
  • {"criterion_text":"- A contraindication for the use of premedication with midazolam"}
  • {"criterion_text":"- A known allergy to midazolam"}
  • {"criterion_text":"- A contraindication for premedication in general"}
  • {"criterion_text":"- A contraindication for the use of a gas-induction/gas-anesthesia"}
  • {"criterion_text":"- A contraindication for the use of sevoflurane"}
  • {"criterion_text":"- A known mental retardation of the child"}
  • {"criterion_text":"- Preoperative behavioral disturbances and psychiatric disorders"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Primary endpoints are the difference in perioperative anxiety between the two groups measured with mYpas-score and parental-scoring with the 5-point anxiety scale.","definition_or_measurement_approach":"Measured using the mYPAS score and parental scoring with a 5-point anxiety scale (parental scoring categories defined elsewhere in the protocol)."}

Secondary endpoints

  • {"endpoint_text":"- Stressful inductions (anesthetic satisfaction) Definition of stressful anesthetic inductions will be qualified by scaling and noted by the anesthesiologist, directly post-induction. XML File Identifier: Mmsidp0h9a5a/NwZENxH2Odvq/w= Page 15/25 1. Cooperative Smooth Induction: no crying, no unrest 2. Passive induction: crying, no unrest 3. Anxious induction: crying and unrest 4. Combative induction: total hysteric 2. Parental scoring for anxiety of the patient","definition_or_measurement_approach":"Anesthesiologist-rated scale recorded immediately post-induction with categories: 1 Cooperative Smooth Induction; 2 Passive induction; 3 Anxious induction; 4 Combative induction. Also parental scoring for anxiety."}
  • {"endpoint_text":"- Parental scoring for anxiety of the patient will be done by the following the 5-point anxiety scale used: 1. Happy (playing) 2. Happy/little worried (playing cautiously) 3. Worried (no playing, silently) 4. Anxious (crying) 5. Hysterical (crying and screaming) Parental scoring will be done, on the daycare preoperative, on the holding, postoperative on the recovery.","definition_or_measurement_approach":"Parental 5-point anxiety scale applied at preoperative daycare, on the holding area, and postoperative recovery."}
  • {"endpoint_text":"- Respiratory postoperative complications Scored directly post-induction and post detubation - Laryngospasm: Four-point scale (17) 1. No Laryngospasm 2. Mild laryngospasm (relieved by jaw thrust and 100% oxygen) 3. Moderate laryngospasm (relieved by 100% oxygen and positive pressure ventilation) 4. Severe laryngospasm (relieved by succinylcholine and intubation)","definition_or_measurement_approach":"Laryngospasm scored on a four-point scale recorded directly post-induction and post-detubation with specified clinical interventions defining severity levels."}
  • {"endpoint_text":"- Bronchospasm/wheezing 1. Yes 2. No • In absence of a scale","definition_or_measurement_approach":"Binary recording of bronchospasm/wheezing (Yes/No)."}
  • {"endpoint_text":"- Parental Satisfaction on the anxiety-management perioperative: measured on holding, after induction, recovery, postop daycare unit. 1. Extremely satisfied 2. Satisfied 3. Neutral 4. Unsatisfied 5. Extremely Unsatisfactory","definition_or_measurement_approach":"Parental satisfaction measured on a 5-point ordinal scale at multiple perioperative timepoints."}
  • {"endpoint_text":"- Postoperative POCIS-Score by leaving the recovery. POCIS is more suitable for young children then the traditional VAS-score (18) See Appendix III of the protocol","definition_or_measurement_approach":"POCIS score assessed at discharge from recovery; protocol appendix referenced for details."}
  • {"endpoint_text":"- Preoperative sedation or negative behavior Evaluation of sedation or possible negative behavior preoperative after midazolam is done by the RASS-score. (19) See Appendix III of the protocol","definition_or_measurement_approach":"RASS score used to evaluate sedation or negative behavior preoperatively after midazolam administration; protocol appendix referenced for details."}

Recruitment

Planned Sample Size
150
Recruitment Window Months
95
Consent Approach
Written informed consent must be provided by the legal parents or caretaker. Subject information and informed consent forms are available in Dutch (NL) and French (FR) as per available documents. Assent by the child is not specified in the available records.

Geography

Total Number Of Sites
1
Total Number Of Participants
150

Belgium

Earliest CTIS Part Ii Submission Date
10-06-2024
Latest Decision Or Authorization Date
10-07-2024
Processing Time Days
30
Number Of Sites
1
Number Of Participants
150

Sites

Site Name
UZ Brussel
Department Name
Anesthesiology
Principal Investigator Name
Domien Vanhonacker
Principal Investigator Email
domien.vanhonacker@uzbrussel.be
Contact Person Name
Domien Vanhonacker
Number Of Participants
150

Sponsor

Primary sponsor

Full Name
UZ Brussel
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Belgium

Investigational products

Investigational Product Name
BUCCOLAM 2.5 mg oromucosal solution
Active Substance
MIDAZOLAM
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Authorised (marketing authorisation number EU/1/11/709/001)
Maximum Dose
1 mg/kg
Investigational Product Name
Midazolam Rowa 2.5 mg oromucosal solution
Active Substance
MIDAZOLAM
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
ORAL USE
Authorisation Status
Authorised (marketing authorisation number PA0074/099/001)
Maximum Dose
1 mg/kg

Related trials

Other published trials that may interest you.